Danaher (NYSE:DHR) Upgraded by UBS Group to Strong-Buy Rating

Danaher (NYSE:DHR) was upgraded by investment analysts at UBS Group to a “strong-buy” rating in a research report issued on Wednesday, Zacks reports.

DHR has been the topic of a number of other reports. Piper Sandler began coverage on shares of Danaher in a report on Thursday, June 11th. They set a “neutral” rating and a $200.00 price objective on the stock. Weiss Ratings raised shares of Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, July 15th. HSBC lowered their target price on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. Finally, Wolfe Research cut Danaher from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $228.91.

Danaher Stock Performance

Shares of NYSE:DHR opened at $200.30 on Wednesday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher has a 1-year low of $160.93 and a 1-year high of $242.80. The stock has a market capitalization of $140.81 billion, a P/E ratio of 35.58, a P/E/G ratio of 2.50 and a beta of 0.78. The business has a 50-day moving average price of $202.65 and a two-hundred day moving average price of $192.08.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.77 EPS. Equities analysts predict that Danaher will post 8.53 earnings per share for the current year.

Hedge Funds Weigh In On Danaher

Large investors have recently bought and sold shares of the company. Sivia Capital Partners LLC increased its holdings in shares of Danaher by 6.3% during the second quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock valued at $397,000 after acquiring an additional 119 shares in the last quarter. First Trust Advisors LP lifted its position in Danaher by 34.5% in the 2nd quarter. First Trust Advisors LP now owns 55,418 shares of the conglomerate’s stock valued at $10,947,000 after acquiring an additional 14,217 shares in the last quarter. Main Street Financial Solutions LLC lifted its position in Danaher by 40.2% in the 2nd quarter. Main Street Financial Solutions LLC now owns 3,088 shares of the conglomerate’s stock valued at $610,000 after acquiring an additional 886 shares in the last quarter. Ieq Capital LLC increased its holdings in Danaher by 64.2% during the 2nd quarter. Ieq Capital LLC now owns 75,714 shares of the conglomerate’s stock worth $14,957,000 after purchasing an additional 29,592 shares in the last quarter. Finally, HUB Investment Partners LLC raised its stake in shares of Danaher by 30.7% in the second quarter. HUB Investment Partners LLC now owns 1,383 shares of the conglomerate’s stock worth $273,000 after purchasing an additional 325 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

About Danaher

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.